Thank you to our speakers, sponsors, and delegates who joined us in Boston, MA for the summit! If you are interested in the 2024 event, please get in touch at

Welcome to the 5th Annual Gene Therapy Analytical Development Summit 2023

Develop, Validate & Implement Robust Analytical Tools to Guarantee Safety, Efficacy, Quality, & Consistency of Gene Therapy Products

As the gene therapy landscape continues to evolve, analytical technologies and capabilities are developing just as rapidly.

With increased scrutiny from regulators, more products entering later-stage development, and continued focus on ensuring therapeutic safety, it is key for analytical scientists to come together at a dedicated forum to benchmark against other gene therapy companies, connect with companies that could outsource some of their work, and keep up to date with and implement the cutting-edge analytical methods developments.

In this context, the 5th Annual Gene Therapy Analytical Development Summit returned as the leading industry-focused forum exploring how the latest analytical methods are being developed and implemented to guarantee the quality, consistency, safety, and efficacy of gene therapy products.

With the largest and most comprehensive program to date, expert presentations spanned bioassays, molecular biologyphysicochemical properties, quality, process development and, for the very first time, dedicated sessions to CMC and regulation at the brand-new regulatory focus day.

This was your must-attend meeting to collaborate ideas, success, and challenges to capitalize on the technological advances in analytical development and deliver the potential of gene therapies to bring safer, efficacious therapies to patients more quickly and effectively.


“This is one of the best conferences I have ever attended as a scientist and vendor. The title is on point and extremely relevant. The audience was highly competent, motivated, and curious”

2022 Attendee, Malvern Panalytical

2023 World-Class Speaker Faculty Includes:

Adam Washburn

Director, Research & Development

Eli Lilly

Amy Henrickson

Research Associate, Department of Chemistry & Biochemistry

University of Lethbridge

Bartlomieg Blus

Bartlomiej Blus

Associate Director, Group Leader

Biomarin Pharmaceuticals


George Bou-Assaf

Associate Director, Analytical & Biophysical Development


Marina Feschenko

Marina Feschenko

Senior Director, Analytical Development, Cell & Gene Therapy

Vertex Pharmaceuticals

Sarah Wassmer

Quality Evaluator, Cells, Gene Therapies and Radiopharmaceuticals Division

Health Canada

Vinay Kondeti

Senior Scientist

BridgeBio Gene Therapy

Wei Cao

Lead Scientist, Analytical Program Development

Spark Therapeutics

Yixin Li

Principal Scientist

Adverum Biotechnologies

Zhenhong Li

Chief Technology Officer


Previously Attending Companies Include:

GTx -216n
GTx -002n
GTx -116n

GTAD was my favorite conference I attended all last year by far! It strikes a great balance between broadness and the topics being narrow enough that all attendees are very engaged. As an attendee this means all the talks are interesting and relevant to my work. As a speaker this means an engaged audience with insightful questions and valuable feedback.

2022 Attendee, Sanofi


2023 Senior Partners: